Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973228 · ClinicalTrials.gov registry record · Phase 3
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
A Phase 3 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 457
- Enrollment target
NCT04973228 is a Phase 3 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 457 participants.
The verdict
NCT04973228, a Phase 3 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 457 participants
- Enrollment target
Study Summary
This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.
Interventions
- DRUG Vehicle Foam
- DRUG Roflumilast Foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04973228
The ClinicalTrials.gov registry entry for NCT04973228 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT04973228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04973228 about?
NCT04973228 is a clinical study titled "Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)". This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.
What is the current status of trial NCT04973228?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 457 participants. The study started on 2021-07-08. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT04973228?
The interventions under investigation include: Vehicle Foam (DRUG), Roflumilast Foam (DRUG).
Who is sponsoring clinical trial NCT04973228?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.